Cancer of Unknown Primary (CUP) identifies a heterogeneous entity characterized by the absence of an identifiable site-specific tumor of origin, early metastatic dissemination, very aggressive behavior, and undifferentiated phenotype. Representing 3-5% of all human cancers, CUPs are still an unsolved clinical problem, with elusive biology and paucity of effective therapies. Initial genomic surveys of CUPs have been presented but no actionable targets have been validated so far in the clinic. Therefore, at present, a semi-agnostic approach of systemic chemotherapy based on general histological features, rather than rational treatment tailored around hypothesis-generating molecular features, is the gold standard. Putting CUPs in the context of cancer precision medicine, as it has been done for other tumor types such as non-small cell lung cancer, remains an unmet clinical need.
Albeit rare, CUPs provide a unique model to study the common denominators of early tumor dissemination from the primary site and to illustrate the fundamental principles of the metastatization process. Accordingly, the 2017 Candiolo CUP Conference will discuss the clinical and biological complexity of CUPs. The meeting will be structured into four sessions: (1) CUPs: Drivers and Targets; (2) Cancer Stem Cells and CUPs: Understanding the Early Metastatic Phenotype; (3) CUPs: Diagnostic and Therapeutic Guidelines; (4). Cancer Precision Medicine in the Metastatic Disease

• Manel Esteller Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL). L'Hospitalet de Llobregat, Barcelona (Spain)
• Christophe Massard Institut Gustave Roussy, University of Paris Sud, Villejuif (France)
• Karin Oien University of Glasgow, Institute of Cancer - Pathology Glasgow (UK)
• Klaus Pantel Universitätsklinikum Hamburg-Eppendorf - Department of Tumor Biology, Hamburg (Germany)
• Christoph A. Klein Experimental Medicine and Therapy Research, University of Regensburg, Regensburg (Germany)
• Andreas Trumpp HI-STEM gGmbH im Deutschen Krebsforschungszentrum DKFZ, Heidelberg (Germany)
• Carla Boccaccio Candiolo Cancer Institute, Cancer Stem Cell Research, Candiolo (Italy)
• Gauri R Varadhachary Department of Gastrointestinal Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston (USA)
• Filippo Montemurro Candiolo Cancer Institute, Investigative Clinical Oncology, Candiolo (Italy)
• Anna Sapino Candiolo Cancer Institute, Pathology Unit, Candiolo (Italy)
• Maurizio Scaltriti Memorial Sloan Kettering Cancer Center - Human Oncology and Pathogenesis Program, New York (USA)
• Livio Trusolino Candiolo Cancer Institute, Translational Cancer Medicine, Candiolo (Italy)


Istituto di Candiolo
Strada Provinciale, 142 km 3,95
10060 Candiolo, Torino-Italy


How to reach the Institute

Visualizza IRCC in una mappa di dimensioni maggiori

Support Us